Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
NCT05626634 · View on ClinicalTrials.gov ↗
Study Summary
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
Conditions Studied
Interventions
- DRUG LP352, bexicaserin
Study Locations (20)
Florida
- Northwest Florida Clinical Research Group — Gulf Breeze
- University of Miami — Miami
- Advent Health Orlando — Orlando
- Research Institute of Orlando — Orlando
- University of South Florida — Tampa
New York
- Boston Children's Health Physicians LLP — Hawthorne
- Northwell Health — New York
- Northeast Regional Epilepsy Group — Staten Island
California
- Rancho Los Amigos National Rehabilitation Center (RLANRC) — Downey
- University of California San Francisco — San Francisco
North Carolina
- OnSite Clinical Solutions LLC — Charlotte
- Wake Forest University School of Medicine — Winston-Salem
Arkansas
- Arkansas Children's Hospital — Little Rock
Hawaii
- Hawaii Pacific Neuroscience — Honolulu
Illinois
- Northwestern University Feinberg School of Medicine — Chicago
Maryland
- Mid-Atlantic Epilepsy and Sleep Center — Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-11-08 |
| Est. Completion | 2024-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05626634
The ClinicalTrials.gov registry entry for NCT05626634 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Longboard Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Dravet Syndrome appearing as the primary indexed condition, and to 1 intervention — of which LP352, bexicaserin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05626634 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, New York, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05626634 about?
NCT05626634 is a clinical study titled "Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy". The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
What is the current status of trial NCT05626634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2022-11-08. Estimated completion is 2024-12-20.
What conditions does trial NCT05626634 study?
This clinical trial studies the following conditions: Dravet Syndrome, Developmental and Epileptic Encephalopathy, Lennox-Gastaut Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05626634?
The interventions under investigation include: LP352, bexicaserin (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05626634?
This trial is sponsored by Longboard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05626634 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.